DDInter583 DDInter596
In 2016, the global burden of dementia was estimated to be 43.8 million, demonstrating a significant increase from a global prevalence of 20.2 million in 1990. Donepezil, also known as Aricept, is a piperidine derivative acetylcholinesterase inhibitor used in the management of the dementia of Alzheimer's Disease, and in some cases, is used to manage other types of dementia. Donepezil was first approved by the FDA in 1996, and its extended-release form was approved in combination with [Memantine] in 2014 to manage moderate and severe forms of Alzheimer's dementia.[L7916,L7937] A donepezil transdermal delivery system, Adlarity, was approved by the FDA in March 2022 for the treatment of Alzheimer's dementia. Though it does not alter the progression of Alzheimer's disease, donepezil is effective in managing the symptoms of its associated dementia.
Doxorubicin is a cytotoxic anthracycline antibiotic isolated from cultures of Streptomyces peucetius var. caesius along side with daunorubicin, another cytotoxic agent, in 1970.[A1575,A257709,A257614] Although they both have aglyconic and sugar moieties, doxorubicin's side chain terminates with a primary alcohol group compared to the methyl group of daunorubicin. Although its detailed molecular mechanisms have yet to be understood, doxorubicin is generally thought to exert its effect through DNA intercalation, which eventually leads to DNA damage and the generation of reactive oxygen species. Thanks to its efficacy and broad effect, doxorubicin was approved by the FDA in 1974 to treat a variety of cancer, including but not limited to breast, lung, gastric, ovarian, thyroid, non-Hodgkin’s and Hodgkin’s lymphoma, multiple myeloma, sarcoma, and pediatric cancers.[A1573,A257614,L45231] However, one of the major side effects of doxorubicin is cardiotoxicity, which excludes patients with poor heart function and requires treatment termination once the maximally tolerated cumulative dose is reached.
Donepezil {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Daunorubicin
Daunorubicin {u} (Compound) resembles {v} (Compound) Doxorubicin
Donepezil {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Idarubicin
Idarubicin {u} (Compound) resembles {v} (Compound) Doxorubicin
Donepezil {u} (Compound) binds {v} (Gene) CYP2D6
CYP2D6 {u} (Gene) is bound by {v} (Compound) Doxorubicin
Donepezil {u} (Compound) upregulates {v} (Gene) RSU1
RSU1 {u} (Gene) is upregulated by {v} (Compound) Doxorubicin
Donepezil {u} (Compound) downregulates {v} (Gene) ARL4C
ARL4C {u} (Gene) is upregulated by {v} (Compound) Doxorubicin
Donepezil {u} (Compound) downregulates {v} (Gene) CANT1
CANT1 {u} (Gene) is downregulated by {v} (Compound) Doxorubicin
Donepezil {u} (Compound) upregulates {v} (Gene) NFKBIA
NFKBIA {u} (Gene) is downregulated by {v} (Compound) Doxorubicin
Donepezil {u} (Compound) causes {v} (Side Effect) Hyperlipidaemia
Hyperlipidaemia {u} (Side Effect) is caused by {v} (Compound) Doxorubicin
Donepezil {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Daunorubicin
Daunorubicin {u} (Compound) resembles {v} (Compound) Valrubicin
Valrubicin {u} (Compound) resembles {v} (Compound) Doxorubicin
Donepezil {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Idarubicin
Idarubicin {u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Daunorubicin
Daunorubicin {u} (Compound) resembles {v} (Compound) Doxorubicin
Donepezil may cause a moderate interaction that could exacerbate diseases when taken with Daunorubicin and Daunorubicin (Compound) resembles Doxorubicin (Compound)
Donepezil may cause a moderate interaction that could exacerbate diseases when taken with Idarubicin and Idarubicin (Compound) resembles Doxorubicin (Compound)
Donepezil (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Doxorubicin (Compound)
Donepezil (Compound) upregulates RSU1 (Gene) and RSU1 (Gene) is upregulated by Doxorubicin (Compound)
Donepezil (Compound) downregulates ARL4C (Gene) and ARL4C (Gene) is upregulated by Doxorubicin (Compound)
Donepezil (Compound) downregulates CANT1 (Gene) and CANT1 (Gene) is downregulated by Doxorubicin (Compound)
Donepezil (Compound) upregulates NFKBIA (Gene) and NFKBIA (Gene) is downregulated by Doxorubicin (Compound)
Donepezil (Compound) causes Hyperlipidaemia (Side Effect) and Hyperlipidaemia (Side Effect) is caused by Doxorubicin (Compound)
Donepezil may cause a moderate interaction that could exacerbate diseases when taken with Daunorubicin and Daunorubicin (Compound) resembles Valrubicin (Compound) and Valrubicin (Compound) resembles Doxorubicin (Compound)
Donepezil may cause a moderate interaction that could exacerbate diseases when taken with Idarubicin and Idarubicin (Compound) resembles Daunorubicin (Compound) and Idarubicin may cause a moderate interaction that could exacerbate diseases when taken with Daunorubicin and Daunorubicin (Compound) resembles Doxorubicin (Compound)